About enGene Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: CA
- Website: https://engene.com
Frequently Asked Questions
What is the 52-week range for ENGN?
The 52-week high is $12.25 and the 52-week low is $1.4.
What is the P/E ratio for ENGN?
The P/E ratio data is currently unavailable.
What is the dividend yield for ENGN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -55.79%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.20.
Analyst Recommendation Trends
Wall Street analyst consensus for ENGN over the last few months:
Latest ENGN News
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
enGene Therapeutics Inc. (ENGN) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 7:00 AM EDTCompany ParticipantsRonald H.
enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market
enGene Therapeutics trades below cash value. Read on to assess risks, cost cuts extending the runway to 2029, and the potential upside to a $6.65 fair value.
Citizens Reiterates Market Perform on enGene Therapeuticsto Market Perform
Citizens analyst Silvan Turkcan reiterates enGene Therapeutics (NASDAQ:ENGN) from Market Perform to Market Perform.
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL, September 08, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates.
enGene Holdings Q3 EPS $(0.47) Misses $(0.43) Estimate
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 17.54 percent increase over losses of $(0.57) per share from
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-22 | Grossman William | +5,102 | $1.97 | $10,051 |
| 2026-06-16 | Heffernan Michael Thomas | +31,000 | - | - |
| 2026-06-16 | BRUNK GERALD A | +31,000 | - | - |
| 2026-06-16 | Astley-Sparke Philip | +31,000 | - | - |
| 2026-06-16 | Glickman Richard M | +31,000 | - | - |
| 2026-06-16 | HASTINGS PAUL J | +31,000 | - | - |
| 2026-06-16 | Zoth Lota S. | +31,000 | - | - |
| 2026-01-30 | CHEUNG ANTHONY TZEYEW | +195,000 | - | - |
| 2026-01-30 | Nichols Alexander Julian | +195,000 | - | - |
| 2026-01-30 | Connolly Joan | +195,000 | - | - |
| 2026-01-30 | Boyd Matthew Ross | +195,000 | - | - |
| 2026-01-30 | Giguere Lee | +195,000 | - | - |
| 2026-01-30 | Buck Jill | +195,000 | - | - |
| 2026-01-30 | Cooper Ronald Harold Wilfred | +801,000 | - | - |
| 2026-01-30 | Daws D. Ryan | +220,000 | - | - |